Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

NeuroMetrix Announces Initial Commercial Shipment of SENSUS™ Pain Management System

NeuroMetrix Inc.
Posted on: 07 Jan 13

NeuroMetrix, Inc. (Nasdaq: NURO),, a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, reported today that it had initiated commercial shipment of its SENSUS Pain Management System which received final FDA clearance on November 28, 2012. SENSUS is a transcutaneous electrical nerve stimulator intended for the symptomatic relief and management of chronic intractable pain. It offers physicians and their patients advanced nerve stimulation technology in a light weight, low profile device worn on the upper calf that is activated by the press of a single button.

“SENSUS was designed to address the clinical and lifestyle needs of people with diabetes. Therefore, we believe that physicians treating patients with painful diabetic neuropathy, a severe and debilitating form of chronic pain, may find SENSUS to be a useful therapeutic option,” said Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix. “We are pleased to be partnering with a growing network of durable medical equipment suppliers who will be responsible for physician detailing, supplying product to patients, and insurance billing. This will allow us to focus on our areas of expertise which include product development, marketing programs, and clinical studies.”

About NeuroMetrix

NeuroMetrix is an innovative medical device company that develops and markets home use and point-of-care devices for the treatment and management of diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation, cause disabling chronic pain, and increase the risk of falling in the elderly. The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States. The company’s products are used by physicians and managed care organizations to optimize patient care and reduce healthcare costs. The company markets the NC-stat® DPNCheck™ device, which is a rapid, accurate, and quantitative point-of-care test for diabetic neuropathy. This product is used to detect diabetic neuropathy at an early stage and to guide treatment. The company also markets the SENSUS™ Pain Management System for treating chronic pain, focusing on physicians managing patients with painful diabetic neuropathy. The company has additional therapeutic products in its pipeline. For more information, please visit

Business Wire

Last updated on: 07/01/2013

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.